Bravelle, approved in May 2002 for the treatment of infertility, is a highly purified, human-derived follicle-stimulating hormone (hFSH) indicated for ovulation induction following pituitary suppression. It is used in conjuction with human chorionic gonadotropin.
Bravelle is available for both subcutaneous and intramuscular injection.
Brevelle was evaluated in a prospective, parallel group, multicenter trial involving 111 oligo-anovulatory subjects undergoing ovulation induction. The trial compared Bravelle to follitropin beta, a recombinant FSH. Subjects first underwent pituitary suppression with a GnRH agonist and were then randomized into three treatment groups: Bravelle subcutaneous (SC), Bravelle intramuscular (IM), and follitropin beta SC. Results of this clinical trial showed no significant differences in safety and efficacy between the treatment groups.
Adverse reactions included ovarian hyperstimulation syndrome (OHSS), with or without pulmonary or vascular complications, which occurred in 8.2% of subjects receiving Brevelle.
For more information about Bravelle, please visit the Ferring Pharmaceuticals web site at: www.ferringusa.com.
The Bravelle (urofollitropin for injection, purified) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.